Andelyn Biosciences has set its sights on Dublin for one of two new labs for the gene therapy company.
In the budding biotech industry, gene therapy is a medical field in which genetic modification of cells is used to treat disease in an individual by introducing repaired or reconstructed genetic material.
Andelyn—a portmanteau after two children who were a part of some gene therapy milestones in the U.S.—grew out of a core facility at Nationwide Children’s Hospital. The company has grown quickly since off-shooting, with Andelyn clients now existing across the country and around the globe.
Andelyn has increased its workforce by about a third just this year, with expectations of doubling or tripling some teams in the next year or two.
Andelyn’s growth, as well as an increase in production, has led them to the construction of a new lab in Dublin.
The new lab will make room for additional workspace and “our ability to manufacture more quality, preclinical and clinical products,” said Dr. Heidi Coia, one of Andelyn’s lead scientists and a project manager in the viral vector core.
More about Andelyn Biosciences:
Providing clients with a consistent quality product. Offering patients life-altering therapies. Our leading-edge technologies help you advance the field of gene and cell-based therapies. Our forward-thinking business model allows us – and you – support the future of child health research.
Public Affairs Officer
614.578.1302 – Cell